This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
ITGR vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. SONVY: Which Stock Is the Better Value Option?
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
by Zacks Equity Research
Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases
Why Integer (ITGR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint
by Zacks Equity Research
Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.
MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio
by Zacks Equity Research
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
by Zacks Equity Research
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
by Zacks Equity Research
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Factors That Make Centene Stock a Lucrative Pick Right Now
by Zacks Equity Research
CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
by Zacks Equity Research
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
by Zacks Equity Research
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
by Zacks Equity Research
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
by Zacks Equity Research
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
by Zacks Equity Research
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
by Zacks Equity Research
ALC ends the first quarter of 2025 on a disappointing note.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
by Zacks Equity Research
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
by Zacks Equity Research
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
PACB Stock May Rise Following the Deal With Chulalongkorn University
by Zacks Equity Research
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.